A revolutionary medical implant is offering hope to patients with advanced dry age-related macular degeneration (AMD), one of the leading causes of blindness in older adults. The PRIMA System, a wireless bionic vision implant, has shown the ability to restore central vision for patients with geographic atrophy (GA), a severe form of AMD that affects more than one million Americans.

Unlike current FDA-approved treatments such as Syfovre or Izervay, which only slow the progression of GA, the PRIMA implant actively replaces lost photoreceptors and can help patients perform functional tasks like reading and recognizing faces. The technology gained international attention in October 2025 following the publication of a major clinical trial in The New England Journal of Medicine, signaling what researchers are calling a paradigm shift in vision restoration.

 

 

The implant, developed by California-based Science Corporation, consists of a tiny, wireless chip just 2mm wide and thinner than plastic wrap. It is surgically placed beneath the damaged portion of the retina, where it acts as an artificial array of light-sensitive cells. The system includes three components: the subretinal implant, augmented-reality glasses equipped with a miniature camera and digital projector, and a pocket processor powered by artificial intelligence. The glasses capture visual scenes and beam them as near-infrared light onto the implant, which then stimulates healthy retinal cells to send information to the brain.

Though the restored vision is black-and-white, blurry, and limited in scope, it allows patients to read slowly and regain the ability to interact with their surroundings. Patients must undergo extensive rehabilitation after surgery to adapt to the new form of vision.

 

 

The PRIMA implant was originally developed by the now-defunct French company Pixium Vision and later acquired by Science Corp., led by Neuralink co-founder Max Hodak. In clinical trials across Europe involving 38 patients with severe vision loss, 80% achieved meaningful visual improvement. On average, participants improved by more than five lines on a standard vision chart, with many reporting the ability to read text, navigate independently, and recognize faces.

One 88-year-old participant from the UK described being able to read small print after seeing only black voids for years. Experts like Dr. Frank Holz and Dr. José-Alain Sahel praised the results as life-changing, and independent reviewers from institutions like the Mayo Clinic and Massachusetts Eye and Ear described the findings as a major leap forward in ophthalmology.

The implant is designed for adults with advanced dry AMD and preserved peripheral vision. It is not effective for other causes of blindness such as optic nerve damage. The procedure takes under two hours, is typically outpatient, and is performed under local anesthesia. The implant is activated one month later.

Although the benefits are promising, there are risks. About half of the patients in the trial experienced early side effects such as increased eye pressure, retinal tears, or bleeding. However, these were generally manageable and resolved without long-term issues. No decline in peripheral vision was observed, and prior studies suggest the device remains safe over four years of use.

 

 

Science Corp. is currently seeking market approval in Europe and discussing future approval pathways with the U.S. FDA. The technology remains investigational in the United States. Pricing has not been disclosed, but similar advanced treatments have previously cost up to $10,000. Patients interested in future eligibility can register with Science Corp. at patients.science.xyz.

Researchers are already working on an enhanced version of the system with improved resolution and wider applications. As development continues, the PRIMA implant could significantly expand the scope of neuro-visual rehabilitation and bring renewed independence to millions affected by severe vision loss.

 

Floating Vimeo Video